Moderna, Inc.(MRNA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MRNA Moderna, Inc.

休市中 05-15 16:00:00 EDT

49.04

-0.99

-1.98%

盘后48.57

-0.47-0.96%

19:58 EDT

最高49.88	最低47.91	成交量723.31万
今开48.43	昨收50.03	日振幅3.94%
总市值193.68亿	流通市值178.16亿	总股本3.95亿
成交额3.52亿	换手率1.99%	流通股本3.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MRNA","market":"US","secType":"STK","nameCN":"Moderna, Inc.","latestPrice":49.04,"timestamp":1778875200000,"preClose":50.03,"halted":0,"volume":7233072,"hourTrading":{"tag":"盘后","latestPrice":48.5715,"preClose":49.04,"latestTime":"19:58 EDT","volume":348119,"amount":17069931.9142,"timestamp":1778889524679,"change":-0.4685,"changeRate":-0.009553,"amplitude":0.013051},"delay":0,"changeRate":-0.019788127123725803,"floatShares":363290461,"shares":394939400,"eps":-8.14,"marketStatus":"休市中","change":-0.99,"latestTime":"05-15 16:00:00 EDT","open":48.43,"high":49.88,"low":47.91,"amount":352194296.93447995,"amplitude":0.039376,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.14,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1779091200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1544158800000,"exchange":"NASDAQ","adjPreClose":50.03,"preHourTrading":{"tag":"盘前","latestPrice":48.34,"preClose":50.03,"latestTime":"09:29 EDT","volume":42107,"amount":2052666.437419,"timestamp":1778851799999,"change":-1.69,"changeRate":-0.03378,"amplitude":0.036912},"postHourTrading":{"tag":"盘后","latestPrice":48.5715,"preClose":49.04,"latestTime":"19:58 EDT","volume":348119,"amount":17069931.9142,"timestamp":1778889524679,"change":-0.4685,"changeRate":-0.009553,"amplitude":0.013051},"volumeRatio":0.49710072860774757,"optionData":{"bulkOrders":[{"symbol":"MRNA","call":true,"expireDate":1778817600000,"strike":"53.0","timestamp":1778857181151,"price":0.02,"volume":3997,"amount":7994,"type":"*"},{"symbol":"MRNA","call":true,"expireDate":1779422400000,"strike":"50.0","timestamp":1778857181151,"price":1.16,"volume":3997,"amount":463652,"type":"-"}]},"impliedVol":0.6939,"impliedVolPercentile":0.2789},"requestUrl":"/m/hq/s/MRNA/wiki","defaultTab":"wiki","newsList":[{"id":"1159058568","title":"异动解读 | Moderna盘中大跌5.14%，汉坦病毒疫苗概念热度消退叠加机构质疑商业前景引发回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1159058568","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159058568?lang=zh_cn&edition=full","pubTime":"2026-05-13 21:58","pubTimestamp":1778680685,"startTime":"0","endTime":"0","summary":"Moderna, Inc.  今日盘中股价大跌5.14%，引起了市场的广泛关注。消息面上，此次股价回调主要源于此前推动股价上涨的汉坦病毒疫苗概念热度消退。投行Evercore ISI发布研报明确指出，汉坦病毒属于低发疾病，市场空间有限，相关事件不太可能为Moderna带来实际营收，股价大幅波动更多是情绪驱动而非基本面变化。此前，受汉坦病毒疫苗临床数据积极及一季度营收超预期推动，公司股价在过去数个交易日内曾累计大幅上涨逾20%。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634291897","title":"汉坦病毒疫情带动Moderna(MRNA)盘前扬升3.18% 机构上调目标价至58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634291897","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634291897?lang=zh_cn&edition=full","pubTime":"2026-05-12 16:55","pubTimestamp":1778576139,"startTime":"0","endTime":"0","summary":"金吾财讯 | Moderna 盘前扬升，截至发稿，最新报54.56美元，上涨3.18%，盘前成交额14.03亿美元。消息面上，独立研究提供商CFRA分析称，在安第斯病毒在邮轮MV Hondius上爆发后，MRNA股票此前已在五天内上涨超过16%。尽管目前尚无针对汉坦病毒的疫苗，但mRNA技术具有包括快速开发、毒株适应性强以及相比传统疫苗可引发更强免疫反应等优势。Moderna正与韩国大学合作开发一种基于mRNA的汉坦病毒疫苗，不过该项目仍处于早期临床前阶段。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/Y2U1MTljZjZkNTgxMTYyODU5MDU0MTEzOA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2U1MTljZjZkNTgxMTYyODU5MDU0MTEzOA==.png"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300289","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UUP","MRNA","UDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143160264","title":"个股聚焦：Moderna、英特尔、MidCap Financial Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=1143160264","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143160264?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:46","pubTimestamp":1778492797,"startTime":"0","endTime":"0","summary":"Moderna  股价在盘前交易中飙升了8%。此前，这家生物医药公司向媒体透露，早在近期一艘邮轮爆发疫情之前，他们就已经启动了针对汉坦病毒的疫苗研发工作。市场对人工智能相关企业的热情持续高涨，推动这两家芯片制造商的股价双双上扬。就在上周五，它们的收盘价均创下了历史新高。据消息，阿波罗全球管理  已就出售其上市业务发展公司 MidCap Financial Investment Corp  进行了谈判。福克斯-A  则是今日计划公布财报的公司之一。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c3eded8fb3ee9cd51304c05def1e555f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0081259029.USD","BK4512","BK4532","LU2543165471.USD","LU2458330243.SGD","LU0127658192.USD","LU2286300806.USD","MULL","IE00B5949003.HKD","IE00B7SZLL34.SGD","MUU","IE000M9KFDE8.USD","BK4527","BK4535","LU2148611432.USD","IE0009356076.USD","LU0056508442.USD","BK4551","BK4612","MRNY","BK4550","LU1803068979.SGD","LU2250418816.HKD","LU0082616367.USD","BK4585","BK4602","LU2089985449.USD","BK4548","LINT","BK4534","LU0321505439.SGD","GB00BDT5M118.USD","BK4588","BK4579","IE00B19Z3B42.SGD","LU0321505868.SGD","MFIC","LU0889565833.HKD","MRNA","LU2211815571.USD","IE00B19Z3581.USD","BK4141","MUD","LU1366333091.USD","INTW","LU0642271901.SGD","BK4554","BK4135","BK4566","LU0154236417.USD","IE0002270589.USD","MU","LU0274383776.USD","LU0157215616.USD","BK4139","LU0889566641.SGD","BK4529","LU1316542783.SGD","APO","BK4515","LU0792757196.USD","LU1323610961.USD","LU2458330169.SGD","LU1852331112.SGD","BK4125","BK4575","LU2360106780.USD","INTC","FOXA","LU0097036916.USD","BK4568","BK4553","LU0203345920.USD","LU0203347892.USD","BK4543","LU2054465674.USD","LU1267930813.SGD","MRNX","04335","LU0719512351.SGD","LU2048586759.USD","BK4605","BK4501","BK4533","LU0109392836.USD","LU2931357623.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106114954","title":"异动解读 | Moderna盘前大涨5.78%，汉坦病毒疫苗临床数据积极叠加营收超预期推动股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1106114954","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106114954?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:05","pubTimestamp":1778486719,"startTime":"0","endTime":"0","summary":"Moderna, Inc.  今日盘前股价大幅上涨5.78%，引起了市场的广泛关注。首先，公司近日公布了其mRNA汉坦病毒疫苗的一期临床试验积极数据，该疫苗耐受性良好，并在所有剂量组中均诱导出了强劲的抗体反应，这验证了其mRNA技术平台应对多种病毒疾病的能力。此外，其在研的mRNA个性化肿瘤治疗性疫苗EVM16的首次人体试验数据也表现积极。这些因素共同增强了市场对Moderna技术领先地位及未来增长潜力的信心，从而推动了股价在盘前走强。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7c550214a914aa5b0d6e74a203b21919","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165332761","title":"异动解读 | Moderna夜盘大涨6.68%，汉坦病毒疫苗临床数据积极叠加营收超预期推动股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1165332761","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165332761?lang=zh_cn&edition=full","pubTime":"2026-05-11 15:27","pubTimestamp":1778484438,"startTime":"0","endTime":"0","summary":"Moderna在今日夜盘交易中大幅上涨6.68%，引起了市场的广泛关注。与此同时，其在研的mRNA个性化肿瘤治疗性疫苗EVM16的首次人体试验数据也表现积极。这些来自研发管线与财务表现的积极信号，显著增强了投资者对Moderna在mRNA领域技术领先地位及未来增长潜力的信心，从而推动了股价在夜盘时段走强。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7c550214a914aa5b0d6e74a203b21919","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192977429","title":"异动解读 | Moderna夜盘大涨6.31%，汉坦病毒疫苗临床数据积极叠加营收超预期推动股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1192977429","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192977429?lang=zh_cn&edition=full","pubTime":"2026-05-11 08:03","pubTimestamp":1778457828,"startTime":"0","endTime":"0","summary":"Moderna (MRNA) 在夜盘交易中大幅上涨6.31%，引起了市场的广泛关注。消息面上，公司近日公布了mRNA汉坦病毒疫苗的一期临床试验积极数据，该疫苗耐受性良好，并在所有剂量组中均诱导出了强劲的抗体反应，验证了其mRNA平台应对多种病毒疾病的能力。此外，公司公布的一季度营收达到3.89亿美元，远超分析师预期的2.28亿美元。与此同时，其mRNA个性化肿瘤治疗性疫苗EVM16的首次人体数据也表现积极，瑞银因此上调了目标价。多重利好因素共振，共同推动了股价的强势表现。这些积极的临床数据和财务表现，进一步增强了市场对Moderna在mRNA技术领域领先地位及其未来增长潜力的信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7c550214a914aa5b0d6e74a203b21919","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100129801","title":"异动解读 | Moderna盘中大涨16.56%，营收超预期及癌症疫苗数据积极提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1100129801","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100129801?lang=zh_cn&edition=full","pubTime":"2026-05-08 23:48","pubTimestamp":1778255333,"startTime":"0","endTime":"0","summary":"Moderna, Inc. (MRNA)今日盘中股价大幅上涨16.56%，引起了市场的广泛关注。消息面上，公司此前公布的一季度营收达3.89亿美元，远超分析师平均预期的2.28亿美元，主要受益于国际新冠疫苗销量强劲增长，公司同时重申了全年营收同比增长10%的目标。此外，公司在AACR会议上披露的mRNA个性化肿瘤治疗性疫苗EVM16首次人体数据表现积极，展现出良好的安全性与初步疗效。瑞银近期上调公司目标价，进一步提振了市场信心。综合来看，强劲的财务表现与积极的研发进展共同推动了Moderna股价在今日交易时段内的大幅攀升。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144457907","title":"Moderna股价大涨逾10%，此前其公布mRNA汉坦病毒疫苗一期临床积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1144457907","media":"老虎资讯综合","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144457907?lang=zh_cn&edition=full","pubTime":"2026-05-08 23:14","pubTimestamp":1778253284,"startTime":"0","endTime":"0","summary":"Moderna周五早盘股价上涨超10%，此前公司公布了其mRNA汉坦病毒疫苗的一期临床积极数据。这一进展重新提振了投资者对Moderna mRNA产品管线的信心。对于Moderna而言，这项数据验证了其mRNA平台应对多种病毒疾病的能力。汉坦病毒一期数据及其对Moderna mRNA平台的意义Moderna针对其研究性汉坦病毒疫苗候选产品开展的一期临床研究显示，该疫苗耐受性良好，未出现严重安全性信号，并在所有剂量组中均诱导出强劲的抗体反应。","market":"us","thumbnail":"https://community-static.tradeup.com/news/fad861c5b82ebcd2a29c6ff47f3e0a8b","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/fad861c5b82ebcd2a29c6ff47f3e0a8b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7c550214a914aa5b0d6e74a203b21919","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Moderna公布mRNA汉坦病毒疫苗一期临床积极数据","news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA","MRNX","MRNY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2633459715","title":"中慧生物-B(02627)：中国药审中心批准MRNA RSV疫苗IND申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2633459715","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633459715?lang=zh_cn&edition=full","pubTime":"2026-05-08 20:57","pubTimestamp":1778245029,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中慧生物-B 发布公告，继集团于2025年11月7日获美利坚合众国食品药品监督管理局批准其于美国提交的新药临床试验申请后，国家药品监督管理局药品审评中心已批准集团自主研发的mRNA RSV疫苗候选产品的IND申请。目前在中国，RSV感染的治疗仍依赖广谱抗病毒药物及对症治疗。因此，迫切需要开发一种有效的RSV疫苗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439772.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","02627","BK4139","BK4534","BK4532","BK4501","BK4548","BK1161","MRNA","BK4588","IND","BK4568","BK4533","159646","BK4551","MRNY","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116879546","title":"异动解读 | Moderna盘前大涨5.14%，营收远超预期叠加肿瘤疫苗数据积极提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1116879546","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116879546?lang=zh_cn&edition=full","pubTime":"2026-05-07 21:18","pubTimestamp":1778159924,"startTime":"0","endTime":"0","summary":"Moderna, Inc. (MRNA) 今日盘前股价大涨5.14%，引起了市场的广泛关注。此次股价上涨主要得益于公司最新公布的财务业绩和研发进展。公司第一季度营收达到3.89亿美元，远超分析师平均预期的2.28亿美元，这主要受益于国际新冠疫苗销量的强劲增长。同时，公司重申了全年营收同比增长10%的目标，表明其正重返销售增长轨道。此外，公司在AACR会议上披露了其mRNA个性化肿瘤治疗性疫苗EVM16的首次人体数据，结果显示该疫苗具有良好的安全性和初步疗效，为投资者带来了积极的信号。多个候选药物也临近监管批准节点，进一步增强了市场对公司未来发展的信心，共同推动了股价的修复与上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167020721","title":"Moderna 的 mRNA 流感疫苗在后期试验中表现优于标准疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=1167020721","media":"老虎资讯综合","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167020721?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:46","pubTimestamp":1778157971,"startTime":"0","endTime":"0","summary":"如果获批，Moderna 的疫苗将成为美国首款采用 mRNA 技术制成的季节性流感疫苗。研究人员表示，两组之间严重副作用发生率基本相当：接种 mRNA 疫苗的人群中为 2.2%，而接种标准剂量疫苗的人群中为 1.9%。今年 2 月，FDA 曾拒绝 Moderna 的申请，原因是对照组所使用的标准剂量流感疫苗存在争议。目前，Moderna 的流感疫苗也正在欧盟、加拿大和澳大利亚接受监管审查。","market":"us","thumbnail":"https://community-static.tradeup.com/news/fad861c5b82ebcd2a29c6ff47f3e0a8b","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/fad861c5b82ebcd2a29c6ff47f3e0a8b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9f673a7486b2730831727fea6d8ee170","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Moderna 的 mRNA 流感疫苗在后期试验中表现优于标准疫苗","news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA","MRNX","MRNY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1102880801","title":"异动解读 | Moderna盘中大涨5.27%，营收超预期及肿瘤疫苗数据积极提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1102880801","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102880801?lang=zh_cn&edition=full","pubTime":"2026-05-04 22:18","pubTimestamp":1777904291,"startTime":"0","endTime":"0","summary":"Moderna（MRNA）今日盘中股价大幅上涨5.27%，引起了市场的广泛关注。消息面上，公司此前公布的第一季度营收为3.89亿美元，远超分析师平均预期的2.28亿美元，主要得益于国际新冠疫苗销量强劲增长。同时，公司重申全年营收同比增长高达10%的预期，并表示将重返销售增长轨道。此外，公司在AACR会议上披露的mRNA个性化肿瘤治疗性疫苗EVM16首次人体数据表现积极，展现出良好的安全性与初步疗效，研发管线中多个候选药物亦临近监管批准节点，进一步提振了市场信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150823990","title":"Moderna高管称公司正等待FDA指导 以恢复流感-新冠联合疫苗美国申报流程","url":"https://stock-news.laohu8.com/highlight/detail?id=1150823990","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150823990?lang=zh_cn&edition=full","pubTime":"2026-05-01 20:24","pubTimestamp":1777638268,"startTime":"0","endTime":"0","summary":"Moderna公司高管近日表示，该公司正在等待美国食品药品监督管理局的进一步指导，以确定恢复流感与新冠联合疫苗在美国申报的后续步骤。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4534","BK4533","MRNA","BK4532","BK4588","BK4585","BK4501","BK4568","BK4548","MRNY","MRNX","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104357139","title":"Moderna公布第一季度每股亏损3.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104357139","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104357139?lang=zh_cn&edition=full","pubTime":"2026-05-01 18:54","pubTimestamp":1777632878,"startTime":"0","endTime":"0","summary":"Moderna公司最新财报显示，第一季度营收达到3.89亿美元，远超华尔街分析师预期的2.28亿美元。尽管营收表现亮眼，公司当季每股亏损为3.40美元，略好于市场预估的每股亏损3.96美元。展望未来，Moderna预计将在2026年恢复销售增长态势，并有望获得包括季节性流感疫苗在内的多项新批准。财务储备方面，Moderna预计到2026年底，现金及投资规模将保持在45亿至50亿美元区间，为后续研发和市场拓展提供有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","BK4551","MRNX","BK4568","MRNA","BK4501","BK4548","BK4585","BK4533","MRNY","BK4139","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120496694","title":"Moderna Q1业绩超预期，重申全年实现10%营收增长计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1120496694","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120496694?lang=zh_cn&edition=full","pubTime":"2026-05-01 18:51","pubTimestamp":1777632719,"startTime":"0","endTime":"0","summary":"5月1日，Moderna盘前一度涨超10%！Moderna 首席执行官 Stéphane Bancel 表示：“Moderna 团队在今年开局良好，在 2025 年采取的行动基础上，实现了显著的收入增长和大幅的成本削减。”“凭借第一季度强劲的增长势头，我们很高兴能在 2026 年恢复销售增长，并期待在全球范围内获得多项额外批准，包括我们的季节性流感疫苗，这将是 Moderna 的第五个获批产品。”Moderna重申了其2026年实现10%营收增长的计划，并维持了其GAAP运营费用削减目标。","market":"us","thumbnail":"https://static.tigerbbs.com/6a8642475395bb363eacb86148917e7b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6a8642475395bb363eacb86148917e7b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5c970505340e4afbf29108a4480b7217","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Moderna Q1业绩超预期，重申全年实现10%营收增长计划","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124230008","title":"异动解读 | Moderna盘前大涨5.35%，营收超预期且预计恢复销售增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1124230008","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124230008?lang=zh_cn&edition=full","pubTime":"2026-05-01 18:40","pubTimestamp":1777632033,"startTime":"0","endTime":"0","summary":"Moderna, Inc. (MRNA) 今日盘前股价大涨5.35%，引起了市场的广泛关注。消息面上，公司公布的第一季度营收为3.89亿美元，远超分析师平均预期的2.28亿美元，这主要得益于国际新冠疫苗销量的强劲增长。同时，公司重申了2026年营收将同比增长高达10%的预期。此外，公司预计将在2026年重返销售增长轨道，其研发管线中多个候选药物即将获得监管批准，包括季节性流感疫苗。公司在AACR会议上披露的mRNA个性化肿瘤治疗性疫苗EVM16的首次人体数据也表现积极，展现了良好的安全性与初步疗效，进一步提振了市场信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5c970505340e4afbf29108a4480b7217","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131327497","title":"Moderna预计2026年恢复销售增长 将获多项新批准含季节性流感疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=1131327497","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131327497?lang=zh_cn&edition=full","pubTime":"2026-05-01 18:31","pubTimestamp":1777631481,"startTime":"0","endTime":"0","summary":"生物技术公司Moderna, Inc.近日宣布，公司预计将在2026年重返销售增长轨道。这一乐观预测基于其研发管线中多个候选药物即将获得的监管批准，其中包括备受关注的季节性流感疫苗。\nModerna管理层表示，除了流感疫苗外，公司还预期在2026年前获得其他几项重要产品的上市许可。这些新产品的陆续获批将为公司注入新的增长动力，帮助其扭转近期销售额下滑的局面。\n该公司强调，其在mRNA技术平台的持续投入正在进入收获期，未来将通过多元化产品组合推动业绩回升。市场分析师认为，若这些预期顺利实现，Moderna有望重新确立其在疫苗领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5c970505340e4afbf29108a4480b7217","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4548","BK4551","BK4585","BK4568","MRNX","BK4139","MRNY","BK4532","BK4588","BK4533","BK4501","MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183848996","title":"异动解读 | 财报发布前市场情绪谨慎，Moderna盘中大跌5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183848996","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183848996?lang=zh_cn&edition=full","pubTime":"2026-04-29 23:55","pubTimestamp":1777478138,"startTime":"0","endTime":"0","summary":"Moderna, Inc. (MRNA) 今日盘中股价大跌5.32%，引起了投资者的广泛关注。消息面上，Moderna即将发布新一季财报。市场一致预期本季度营收将实现同比增长，但调整后每股收益和息税前利润(EBIT)预计均为负值。同时，公司上季度的毛利率与净利率也处于深度负值区间，盈利压力依然突出。因此，机构观点整体偏谨慎，临近财报发布，市场避险情绪显著升温。市场焦点主要集中于其mRNA呼吸道疫苗的商业化进展以及公司的费用控制节奏。此次股价波动反映了投资者在关键财务数据公布前的担忧与观望态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161886361","title":"财报前瞻｜Moderna, Inc.本季度营收预计增126.11%，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1161886361","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161886361?lang=zh_cn&edition=full","pubTime":"2026-04-24 08:44","pubTimestamp":1776991454,"startTime":"0","endTime":"0","summary":"Moderna, Inc.将于2026年05月01日发布新一季财报，市场聚焦mRNA呼吸道疫苗商业化进展与费用控制节奏。市场一致预期本季度公司营收为2.40亿美元，同比增长126.11%，调整后每股收益为-2.73元，同比增长12.89%，EBIT为-10.10亿美元，同比增长20.23%；公司层面披露的本季度毛利率、净利润或净利率暂无明确前瞻数据。上季公司实现营收6.78亿美元，同比下降29.81%；毛利率为-80.97%；归属于母公司股东的净利润为-8.26亿美元，净利率-121.83%；调整后每股收益为-2.11元，同比增长27.49%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Moderna, Inc.本季度营收预计增126.11%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176389186","title":"英国药品监管机构批准Enflonsia用于预防新生儿及婴儿呼吸道合胞病毒感染","url":"https://stock-news.laohu8.com/highlight/detail?id=1176389186","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176389186?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:14","pubTimestamp":1776856452,"startTime":"0","endTime":"0","summary":"英国药品和健康产品管理局（MHRA）近日宣布，已正式批准Enflonsia（clesrovimab-cfor）用于新生儿及婴儿群体的呼吸道合胞病毒（RSV）预防。\n根据监管机构官网披露的信息，该药物适用于12月龄以下的婴幼儿，可在其首个RSV流行季全程提供保护。这项批准为婴幼儿呼吸道合胞病毒的预防提供了新的医疗方案。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014542.SGD","LU0965509101.SGD","LU2125154778.USD","LU0289739699.SGD","SG9999001176.SGD","LU0006306889.USD","LU1035773651.USD","LU2461242641.AUD","LU2089984988.USD","LU0868494708.USD","BK4559","LU0098860793.USD","LU1057294990.SGD","LU1093756168.USD","LU2357627491.SGD","LU2468319806.SGD","LU1934455277.USD","BK4588","LU1934455863.HKD","LU1037948897.HKD","LU0965509010.AUD","LU0203347892.USD","IE00BJT1NW94.SGD","LU1941712264.USD","LU1116320901.HKD","LU1066051811.HKD","LU1430594728.SGD","IE00BFTCPJ56.SGD","LU2361045086.USD","IE00BLSP4239.USD","LU0058720904.USD","IE00BBT3K403.USD","LU1989771016.USD","LU0266013472.USD","LU1929549753.HKD","LU1699723380.USD","LU0211331839.USD","LU0965508806.USD","LU1983299246.USD","SG9999001440.SGD","IE00B1BXHZ80.USD","LU0985320562.USD","IE00B2B36J28.USD","LU1989772923.USD","LU0265550946.USD","LU1061106388.HKD","LU1291159041.SGD","IE00BSNM7G36.USD","BK4516","SG9999015341.SGD","LU2112291526.USD","MRNA","LU1037948541.HKD","IE0002141913.USD","LU1941712348.USD","LU0320765489.SGD","LU1934455194.USD","LU0208291251.USD","LU0130517989.USD","LU0980610538.SGD","SG9999014567.USD","IE00BN8TJ469.HKD","LU2360032135.SGD","BK4534","IE000M9KFDE8.USD","LU2361044949.HKD","IE00BJJMRZ35.SGD","LU0320765646.SGD","IE00B4R5TH58.HKD","LU1023059063.AUD","LU1066051225.USD","BK4533","BK4007","SG9999014559.SGD","LU0106261372.USD","LU1974910355.USD","LU0122379950.USD","LU1162221912.USD","LU2125154935.USD","LU1069347547.HKD","LU0203345920.USD","LU1066053197.SGD","LU2324357040.USD","LU0648001328.SGD","LU0070302665.USD","LU0868494617.USD","BK4550","LU0432979614.USD","LU2361044865.SGD","LU2023250843.SGD","LU0265550359.USD","LU0942090050.USD","LU1571399168.USD","LU2106854487.HKD","LU0130102774.USD","LU0234572021.USD","LU0861579265.USD","LU2023250504.SGD","IE0009355771.USD","SG9999013999.USD","LU1201861249.SGD","SG9999001176.USD","LU1585245621.USD","LU1989772840.SGD","SG9999015358.SGD","SG9999014575.USD","LU1066051498.USD","SGXZ57979304.SGD","IE00BLSP4452.SGD","LU0238689110.USD","LU1917777945.USD","SG9999002232.USD","LU0859254822.USD","LU1116320737.USD","SG9999002224.SGD","LU0965509283.SGD","LU1093756325.SGD","LU0477156953.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.modernatx.com;www.investors.modernatx.com","stockEarnings":[{"period":"1week","weight":-0.0977},{"period":"1month","weight":-0.0962},{"period":"3month","weight":0.1613},{"period":"6month","weight":0.9798},{"period":"1year","weight":1.0736},{"period":"ytd","weight":0.6629}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Moderna, Inc.于2016年7月22日根据特拉华州法律注册成立。该公司是信使核糖核酸（信使核糖核酸）医学领域的领导者。通过在科学、技术和健康的交叉领域工作十多年，该公司以前所未有的速度和效率开发出药物，包括最早和最有效的新冠疫苗之一。该公司的mRNA平台已使传染病、免疫肿瘤学、罕见病和自身免疫性疾病的疗法和疫苗的开发成为可能。凭借独特的文化和由Moderna价值观和思维模式驱动的全球化团队，以负责任的方式改变人类健康的未来，该公司努力通过mRNA药物向人们传递尽可能大的影响。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.112326},{"month":2,"riseRate":0.375,"avgChangeRate":0.016129},{"month":3,"riseRate":0.5,"avgChangeRate":0.01856},{"month":4,"riseRate":0.625,"avgChangeRate":0.096502},{"month":5,"riseRate":0.625,"avgChangeRate":0.062851},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.025027},{"month":7,"riseRate":0.714286,"avgChangeRate":0.106584},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.089569},{"month":9,"riseRate":0.571429,"avgChangeRate":-0.018964},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.032236},{"month":11,"riseRate":0.714286,"avgChangeRate":0.206001},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.033274}],"exchange":"NASDAQ","name":"Moderna, Inc.","nameEN":"Moderna, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Moderna, Inc.(MRNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Moderna, Inc.(MRNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Moderna, Inc.,MRNA,Moderna, Inc.股票,Moderna, Inc.股票老虎,Moderna, Inc.股票老虎国际,Moderna, Inc.行情,Moderna, Inc.股票行情,Moderna, Inc.股价,Moderna, Inc.股市,Moderna, Inc.股票价格,Moderna, Inc.股票交易,Moderna, Inc.股票购买,Moderna, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Moderna, Inc.(MRNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Moderna, Inc.(MRNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}